Last month Andrew Carr, president of Amersham Biosciences, told GT readers that his main goal for the year would be to bring the “discovery systems” portion of his business into profit by 2004. Now his boss, Amersham CEO William Castell, is making it perfectly clear he agrees that Carr’s attentions should be focused on the company’s only unprofitable division: in March Castell took away the profitable half of Carr’s concern — the protein separations division — and put someone else in charge.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.